Phase 1 Evaluation of GSK2857916 Combined with Standard of Care in Newly Diagnosed Multiple Myeloma Patients

The primary objective of this study is to evaluate the safety and tolerability of **GSK2857916** in combination with standard of care in patients with first-line **Multiple Myeloma**. This is clinically relevant as it aims to determine the potential of GSK2857916 to enhance treatment outcomes when used alongside established therapies, potentially offering a new therapeutic option for patients with this condition.

The clinical trial involves a total of **54 participants** diagnosed with **Multiple Myeloma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial aims to gather data pertinent to this demographic, but further specifics regarding the selection process or health status are not disclosed.

The clinical trial is a **phase 3** study designed to evaluate the efficacy and safety of a treatment regimen in patients with **Multiple Myeloma**. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from May 18, 2020, to March 31, 2025, encompassing both the recruitment and follow-up periods. Participants will be involved in the study for the entire duration unless specific conditions necessitate early termination, such as adverse events or withdrawal of consent.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and any potential side effects. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial concludes with an end-of-study visit, where final assessments are conducted to evaluate the overall outcomes and safety of the treatment regimen.

Participants are expected to adhere to the study protocol throughout their involvement. Conditions that may lead to early termination from the study include non-compliance with the protocol, development of significant health issues, or any other factors that, in the opinion of the investigators, warrant discontinuation for the safety of the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the well-being of all participants.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to conclude by March 31, 2025, with recruitment having commenced on May 18, 2020. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data, adhering to the standards expected in a Phase 3 clinical trial. The trial's design and execution will be aligned with regulatory requirements to ensure the reliability and validity of the efficacy outcomes.